MARKET

TMBR

TMBR

Timber Pharmaceuticals Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

0.2550
+0.0048
+1.92%
After Hours: 0.2550 0 0.00% 16:50 05/27 EDT
OPEN
0.2550
PREV CLOSE
0.2502
HIGH
0.2590
LOW
0.2459
VOLUME
153.91K
TURNOVER
0
52 WEEK HIGH
1.410
52 WEEK LOW
0.2306
MARKET CAP
16.24M
P/E (TTM)
-0.9615
1D
5D
1M
3M
1Y
5Y
Timber Pharmaceuticals GAAP EPS of -$0.05
Timber Pharmaceuticals press release (NYSE:TMBR): Q1 GAAP EPS of -$0.05. Grant Revenue of $0.08M (+100.0% Y/Y). Timber ended the first quarter with $13.9 million in cash 
Seekingalpha · 05/12 20:49
Timber Pharmaceuticals Q1 EPS $(0.05), Same YoY, Sales $83.18K Up From $40.73K YoY
Timber Pharmaceuticals (AMEX:TMBR) reported quarterly losses of $(0.05) per share. This is unchanged from the same period last year. The company reported $83.18 thousand in sales this quarter. This is a 104.20 percent
Benzinga · 05/12 20:38
Timber Pharma jumps after FDA fast track nod for TMB-001 to treat ichthyosis skin diseases
Timber Pharmaceuticals (NYSE:TMBR) on Thursday said that the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to the company's lead asset TMB-001 for the treatment of severe
Seekingalpha · 04/28 12:58
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 04/28 12:52
Timber Pharmaceutical Gets FDA Fast Track designation for TMB-001 in Severe Subtypes of Congenital Ichthyosis
Timber Pharmaceuticals, Inc. (NYSE: TMBR)  announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TMB-001 for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis lamel...
Benzinga · 04/28 12:36
Timber Pharmaceuticals Announces Fast Track Designation Granted By FDA For TMB-001 In Severe Subtypes Of Congenital Ichthyosis
Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE:TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan
Benzinga · 04/28 12:01
BRIEF-Timber Pharmaceuticals Inc - Expects To Initiate A Phase 3 Clinical Trial For TMB-001 In Q2 Of 2022
reuters.com · 04/25 21:24
Timber Pharmaceuticals GAAP EPS of -$0.27, revenue of $0.89M
Timber Pharmaceuticals press release (NYSE:TMBR): FY GAAP EPS of -$0.27. Revenue of $0.89M (+97.8% Y/Y).
Seekingalpha · 03/31 21:55
More
No Data
Learn about the latest financial forecast of TMBR. Analyze the recent business situations of Timber Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TMBR stock price target is 2.250 with a high estimate of 2.250 and a low estimate of 2.250.
High2.250
Average2.250
Low2.250
Current 0.2550
EPS
Actual
Estimate
-0.58-0.43-0.29-0.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2021
Institutional Holdings
Institutions: 16
Institutional Holdings: 880.79K
% Owned: 1.38%
Shares Outstanding: 63.68M
TypeInstitutionsShares
Increased
5
172.81K
New
5
78.64K
Decreased
5
557.09K
Sold Out
7
10.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/President/Chief Executive Officer/Director
John Koconis
Chief Financial Officer/Executive Vice President/Treasurer
Joseph Lucchese
Executive Vice President
Alan Mendelsohn
Director
Zachary Rome
Independent Director
David Cohen
Independent Director
Lubor Gaal
Independent Director
Gianluca Pirozzi
Independent Director
Edward Sitar
No Data
No Data
About TMBR
Timber Pharmaceuticals, Inc. (Timber) is a clinical-stage biopharmaceutical company. It is focused on development of treatments for orphan dermatologic diseases. It Is also focused on developing non-systemic treatments for dermatologic diseases, including congenital ichthyosis, facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma. The Company's pipeline programs include TMB-001, TMB-002 and TMB-003. TMB-001 is topical formulation of isotretinoin, evaluated in a Phase II b clinical trial for the treatment of congenital ichthyosis (CI), a genetic keratinization. TMB-002 is a topical formulation of rapamycin, evaluated in a Phase II b clinical trial for the treatment of FAs in TSC, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. TMB-003 is a formulation of sitaxsentan in the preclinical development for the treatment of scleroderma, a rare connective tissue disorder characterized by abnormal thickening of the skin.

Webull offers kinds of Timber Pharmaceuticals Inc stock information, including AMEX:TMBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TMBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TMBR stock methods without spending real money on the virtual paper trading platform.